Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Discrepancy of Bone Metastases between F-18 FDG PET/CT and Bone Scan in a Patient with Prostate Cancer

전립선암에서 골전이 진단에 대한 F-18 FDG PET/CT와 골스캔의 불일치

  • Choi, Seung-Jin (Department of Nuclear Medicine, Inha University College of Medicine) ;
  • Kim, Chul-Soo (Department of International Medicine, Inha University College of Medicine) ;
  • Byun, Sung-Su (Department of Radiology, Inha University College of Medicine) ;
  • Hyun, In-Young (Department of Nuclear Medicine, Inha University College of Medicine)
  • 최승진 (인하대학교 의과대학 핵의학교실) ;
  • 김철수 (인하대학교 의과대학 내과학교실) ;
  • 변성수 (인하대학교 의과대학 방사선과학교실) ;
  • 현인영 (인하대학교 의과대학 핵의학교실)
  • Published : 2006.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

We report the case of a 73-year-old man who had prostate cancer with bone metastases. Tc-99m HDP Whole body bone scan revealed multiple areas of increased bony uptake consistent with widespread bone metastases. F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated mild F-18 FDG uptake in the lymph nodes of neck, abdomen, and pelvis. However, abnormal F-18 FDG uptake was not seen in the skeletal system. Biopsy and immunohistochemical stains of left supraclavicular mass showed metastatic prostate adenocarcinoma. Currently, there are a few reported cases of F-18 FDG PET/CT evaluation of bone metastases in prostate cancer. We discuss the discrepancy between F-18 FDG PET/CT and bone scan in the detection of osseous metastases of prostate cancer.

Keywords

References

  1. Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55 https://doi.org/10.1016/j.ejrad.2005.01.016
  2. Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003;415s:s120-8 https://doi.org/10.1097/01.blo.0000093051.96273.7c
  3. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetinm-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8 https://doi.org/10.1007/s00432-002-0342-5
  4. Shreve PD, Grossman HB, Gross MD, Warl RL. Metastatic prostate cancer: initial finding of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6 https://doi.org/10.1148/radiology.199.3.8638000
  5. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003;28:302-7 https://doi.org/10.1097/00003072-200304000-00007
  6. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9 https://doi.org/10.1200/JCO.1998.16.10.3375
  7. O'Sullivan JM, Cook GJR. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46:152-9